Endorecherche. Inc.
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
3
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Jan 4 to 28, 2027 · next Jan 4
- 1 fee due Aug 4, 2027The maintenance fee for Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM (US 10,548,903) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 1 fee due Sep 15, 2027The maintenance fee for 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators (US 9,284,345) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 23, 2026
- Sep 27 US 11,452,731 A Method of Treating and Preventing Loss of Cognition · lapsed on the fee record
- Sep 13 US 8,168,627 Helix 12 directed non-steroidal antiandrogens · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,709,516 | Helix 12 directed non-steroidal antiandrogens In force · USPTO record | In force | USPTO record | |
| US 9,090,651 | Helix 12 directed pharmaceutical products In force · USPTO record | In force | USPTO record | |
| US 10,342,805 | Treatment of Alzheimer's Disease, Loss of Cognition, Memory Loss and Dementia with Sex Steroid Precursors in Combination with Selective Estrogen Receptor Modulators In force · High confidence | In force | High confidence | |
| US 9,284,345 | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators In force · USPTO record | In force | USPTO record | |
| US 11,576,891 | Methods of Treating or Preventing Estrogen-Related Diseases In force · High confidence | In force | High confidence | |
| US 10,548,903 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM In force · USPTO record | In force | USPTO record | |
| US 11,690,852 | Reduction of the incidence or recurrence of breast cancer in postmenopausal women treated with intravaginal sex steroid precursor In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 7: 5 patents in force now held by others · 15 lapsed for an unpaid fee · 53 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 abandoned · 16 no status recorded
Rows 11 to 18 of 18 are for members. The first 10 are on the company page.
Pro members see all 18 published applications.